The move affects the ongoing open label extension (OLE) part of the pivotal Phase 3 ZAF-311 bestPWS trial in patients with Prader-Willi syndrome (PWS). A complete clinical hold
Investors in the Series B financing round include the Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Foresite Capital and Kravis Investment Partners. ORIC will use the financing
The NDA submission was based on data from two bioavailability studies. The existing dosing for Viekira Pak is twice daily, three tablets in the morning and one in
About 12,000 patients were enrolled at over 470 sites in eight countries. The five-year study will evaluate the impact of long-term treatment with Belviq CIV on the occurrence
Retinoblastoma generally affects children before the age of three. It is rarely found in adults. Cellceutix said the eye cancer is sight threatening and potentially fatal if not
VAP-1 is a cell-adhesion molecule that may be effective in the treatment of inflammatory diseases. The VAP-1 inhibitor is currently in phase II clinical development. The deal grant
A biologics license application (BLA) was submitted to the US Food and Drug Administration (FDA), while a Grouped Type II variation/extension application was filed with the European Medicines
CGS-200 is a novel high-strength topical formulation of the TRPV1 channel agonist trans-capsaicin combined with hyaluronic acid. It has been designed to deliver long-term desensitization of nerve fibers
The approval, which authorizes the sale of the product in all 28 member states of the European Union, follows the positive opinion from the European Medicines Agency’s Committee
Under the collaboration, the companies will research and develop potential new medicines directed at about 10 GPCR targets. Heptares will apply its GPCR structure-guided platform to help offer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.